Full Press Release Details
Bacterin International Holdings,
Inc. Schedules Third Quarter 2012 Financial Earnings Conference Call
BELGRADE, Mont. Oct. 23, 2012 - Bacterin
International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial
coatings for medical applications, will release its financial results for the three and 9 months ended September 30, 2012 after
the close of regular market trading on Wednesday, November 7, 2012. A conference call will follow at 4:30 p.m. Eastern Time (1:30
Conference Call Details:
Date: Thursday, November 7, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-877-941-1429
International: 1-480-629-9857
Conference ID#: 4572762
The conference call will be broadcast
simultaneously and available for replay here and at the investor section of the
company's Web site at http://www.bacterin.com/index.htm.
Please call the conference telephone
number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty
connecting with the conference call, please contact Hayden IR at 1-646-755-7412.
A replay of the call will be available
after 7:30 p.m. Eastern time on the same day and until December 7 , 2012.
Replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay pin number: 4572762
About Bacterin International
Bacterin International Holdings,
Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's
proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral
repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief
of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral
repair in knee and other joint surgeries.
Bacterin's Medical Device division
develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating
initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further
information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking
This news release contains certain
disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive
in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target," "prospects,"
"potential," "optimistic," "confident," "likely," "probable" or similar expressions
or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these
statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of
important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability
to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under
existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications,
products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results;
the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the
Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to
attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and
regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional
risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes
no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events, except as required by law.
James Carbonara, Regional Vice President,
Brett Maas, 646-536-7331